MAN-02(MAN-02) - 在研适应症：急性肾损伤_专利_临床

概要

基本信息

药物类型

化学药

别名

靶点-

作用机制-

治疗领域

泌尿生殖系统疾病

在研适应症

急性肾损伤

非在研适应症-

原研机构

Q BioMed, Inc.

在研机构

Q BioMed, Inc.

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 MAN-02 相关的临床结果

登录后查看更多信息

100 项与 MAN-02 相关的转化医学

登录后查看更多信息

100 项与 MAN-02 相关的专利（医药）

登录后查看更多信息

1

项与 MAN-02 相关的文献（医药）

2010-04-01·In Vitro Cellular & Developmental Biology - Animal4区 · 生物学

Derivation of Man-1 and Man-2 research grade human embryonic stem cell lines

4区 · 生物学

Article

作者: Maria V. Camarasa ; Melissa A. Baxter ; Tristan R. Mckay ; Sharon F. Sneddon ; Robbie W. Kerr ; Daniel R. Brison ; Fiona Small ; Lisa Shaw ; Nicola Bates ; Susan J. Kimber ; Rachel A. Oldershaw

We report here the derivation of two new human embryonic stem cell lines, Man-1 and Man-2, and their full characterization as novel pluripotent stem cell lines. Man-1 was derived from an embryo surplus to requirement from routine IVF, while Man-2 was obtained from an oocyte classified as failed to fertilise and subsequently chemically activated. We report the characterisation of pluripotency and the differentiation potential of these lines. Work is in progress to establish novel methods of stem cell derivation and culture, which will avoid the use of xenobiotics and be relevant to clinical production of human embryonic stem cell lines. Both newly derived human embryonic stem cell lines will be available for the research community from the UK Stem Cell Bank (http://www.ukstemcellbank.org.uk).

100 项与 MAN-02 相关的药物交易

登录后查看更多信息